Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 71

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 71
---
31/2032 | ​ | ​ |
| ​                    | ​ | ​ | ​                | ​ | 2/11/2021 | ​ | ​ | ​ | ​                       | ​ | 2/10/2021(3)  | ​ | ​ | ​ | ​                                                              | ​ |  18,750 | ​ | ​ | ​ | ​                                                                | ​ |   1,250 | ​ | ​ | ​ | ​                                                                                       | ​ |       — | ​ | ​ | ​ | ​                                | ​ | 64.15 | ​ | ​ | ​ | ​                    | ​ | 2/10/2031 | ​ | ​ |
| ​                    | ​ | ​ | ​                | ​ | 4/7/2020  | ​ | ​ | ​ | ​                       | ​ | 1/1/2020(3)   | ​ | ​ | ​ | ​                                                              | ​ |   8,002 | ​ | ​ | ​ | ​                                                                | ​ |       — | ​ | ​ | ​ | ​                                                                                       | ​ |       — | ​ | ​ | ​ | ​                                | ​ | 16.00 | ​ | ​ | ​ | ​                    | ​ | 4/7/2030  | ​ | ​ |
| ​                    | ​ | ​ | ​                | ​ | 9/19/2019 | ​ | ​ | ​ | ​                       | ​ | 9/19/2019(3)  | ​ | ​ | ​ | ​                                                              | ​ |   2,304 | ​ | ​ | ​ | ​                                                                | ​ |       — | ​ | ​ | ​ | ​                                                                                       | ​ |       — | ​ | ​ | ​ | ​                                | ​ |  0.48 | ​ | ​ | ​ | ​                    | ​ | 9/18/2029 | ​ | ​ |

49

TABLE OF CONTENTS

(1) All of the option awards listed in the table above granted prior to the pricing of our IPO on April 7, 2020 were granted under our 2017 Plan and all of the option awards granted on or after the pricing of our IPO were granted under our 2020 Plan. (2) The option award is eligible to vest contingent upon the achievement of two rigorous development goals, as further described under “Compensation Discussion and Analysis — Elements of Our 2024 Executive Compensation Program — Equity